PharmNovo raises $4M at a lower valuation, triggering KDventures write-down
What's the deal? Swedish neuropathic pain drug developer PharmNovo has raised roughly SEK 39 million ($4 million) in a late-stage round with participation from external investors. Listed backer KDventures announced the raise on July 9, 2026, and wrote down its holding in the company to SEK 5 million.
Why the write-down? The round valued PharmNovo below its previous financing. Under KDventures' valuation guidelines, an unlisted portfolio company is marked at the price paid by a third-party investor in its most recent round — so a lower price triggers a markdown.
By the numbers: The step-down is stark. Following the write-down, KDventures' net asset value per share stood at SEK 0.89 as of June 30, and it now holds a 5% direct stake in PharmNovo.
What's the money for? The capital funds PharmNovo's planned phase 2 study of PN6047, a candidate for neuropathic pain. Nerve pain affects up to 10% of the population, with current treatments often ineffective and carrying significant side effects.
What's the endgame? PN6047 targets the delta opioid receptor rather than the receptor hit by conventional opioids, aiming to cut chronic pain without side effects such as physical dependence and, in severe cases, fatal respiratory depression. A completed phase 1 study showed the drug was safe and well-tolerated, and the phase 2 trial is expected to start in the second half of 2026.
Chairman Anders Hallberg framed the markdown as a matter of discipline. "While the write-down is regrettable, it is a critical matter of trust that our balance sheet accurately reflects the value of our portfolio companies," he said.
What could go wrong? A down round signals investor caution, and clinical-stage biotech remains high-risk — phase 2 results are far from guaranteed. For KDventures, the hit lands on net asset value, though CEO Viktor Drvota called the raise "an important and positive step for PharmNovo ahead of the planned phase 2 study."
The signal: The deal captures the tension facing listed venture holders: transparent, mark-to-market valuations mean that fresh capital at a lower price forces immediate paper losses, even when the underlying company advances toward a key clinical milestone.
Image credit: foteih
